This is the authors' abstract. We don't add key points for this paper.
Sequence-regulating polyhydroxyalkanoate synthase PhaC AR is a chimeric enzyme comprising PhaCs from Aeromonas caviae and Ralstonia eutropha ( Cupriavidus necator ). It spontaneously synthesizes a short-chain-length (SCL, ≤C 5 ) block copolymer poly(2-hydroxybutyrate)- b -poly(3-hydroxybutyrate) [P(2HB)- b -P(3HB)] from a mixture of monomer substrates. In this study, directed evolution of PhaC AR was performed to increase its activity toward a medium-chain-length (MCL, C 6–12 ) monomer, 3-hydroxyhexanoyl (3HHx)-coenzyme A (CoA). Random mutagenesis and selection based on P(3HB- co -3HHx) production in Escherichia coli found that beneficial mutations N149D and F314L increase the 3HHx fraction. The site-directed saturation mutagenesis at position 314, which is adjacent to the catalytic center C315, demonstrated that F314H synthesizes the P(3HHx) homopolymer. The F314H mutant exhibited increased activity toward 3HHx-CoA compared with the parent enzyme, whereas the activity toward 3HB-CoA decreased. The predicted tertiary structure of PhaC AR by AlphaFold2 provided insight into the mechanism of the beneficial mutations. In addition, this finding enabled the synthesis of a new PHA block copolymer, P(3HHx)- b -P(2HB). Solvent fractionation indicated the presence of a covalent linkage between the polymer segments. This novel MCL–SCL block copolymer considerably expands the range of the molecular design of PHA block copolymers.
No takes yet. Share an insight, caveat, or question.
Phan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: